Suppression of acute herpetic pain-related responses by the kappa-opioid receptor agonist (-)-17-cyclopropylmethyl-3,14beta-dihydroxy-4,5alpha-epoxy-beta-[n-methyl-3-trans-3-(3-furyl) acrylamido] morphinan hydrochloride (TRK-820) in mice
- PMID: 14711930
- DOI: 10.1124/jpet.103.059816
Suppression of acute herpetic pain-related responses by the kappa-opioid receptor agonist (-)-17-cyclopropylmethyl-3,14beta-dihydroxy-4,5alpha-epoxy-beta-[n-methyl-3-trans-3-(3-furyl) acrylamido] morphinan hydrochloride (TRK-820) in mice
Abstract
(-)-17-Cyclopropylmethyl-3,14beta-dihydroxy-4,5alpha-epoxy-6beta-[N-methyl-3-trans-3-(3-furyl) acrylamido] morphinan hydrochloride (TRK-820) is a kappa-opioid receptor agonist that has pharmacological characteristics different from typical kappa-opioid receptor agonists. This study was conducted to determine the antiallodynic and antihyperalgesic effects of TRK-820 in a mouse model of acute herpetic pain and to compare them with those of the kappa-opioid receptor agonist enadoline and the mu-opioid receptor agonist morphine. Percutaneous inoculation with herpes simplex virus type-1 induced tactile allodynia and mechanical hyperalgesia in the hind paw on the inoculated side. TRK-820 (0.01-0.1 mg/kg p.o.), enadoline (1-10 mg/kg p.o.) and morphine (5-20 mg/kg p.o.) dose dependently inhibited the allodynia and hyperalgesia, but the antiallodynic and antihyperalgesic dose of enadoline markedly decreased spontaneous locomotor activity. The antinociceptive action of TRK-820 (0.1 mg/kg) was completely antagonized by pretreatment with norbinaltorphimine, a kappa-opioid receptor antagonist, but not by naltrexone, a mu-opioid receptor antagonist. Repeated treatment with morphine (20 mg/kg, four times) resulted in the reduction of antiallodynic and antihyperalgesic effects, whereas the inhibitory potency of TRK-820 (0.1 mg/kg) was almost the same even after the fourth administration. There was no cross-tolerance in antinociceptive activities between TRK-820 and morphine. Intrathecal and intracerebroventricular, but not intraplantar, injections of TRK-820 (10-100 ng/site) suppressed the allodynia and hyperalgesia. These results suggest that TRK-820 inhibits acute herpetic pain through kappa-opioid receptors in the spinal and supraspinal levels. TRK-820 may have clinical efficacy in acute herpetic pain with enough safety margins.
Similar articles
-
The novel kappa-opioid receptor agonist TRK-820 has no affect on the development of antinociceptive tolerance to morphine in mice.Eur J Pharmacol. 2000 Apr 7;394(1):91-5. doi: 10.1016/s0014-2999(00)00139-4. Eur J Pharmacol. 2000. PMID: 10771039
-
Pharmacological properties of TRK-820 on cloned mu-, delta- and kappa-opioid receptors and nociceptin receptor.Eur J Pharmacol. 1999 Jul 2;376(1-2):159-67. doi: 10.1016/s0014-2999(99)00369-6. Eur J Pharmacol. 1999. PMID: 10440101
-
Blockade of mu-opioid receptor-mediated G-protein activation and antinociception by TRK-820 in mice.Eur J Pharmacol. 2003 Feb 7;461(1):35-9. doi: 10.1016/s0014-2999(03)01299-8. Eur J Pharmacol. 2003. PMID: 12568913
-
Possible pharmacotherapy of the opioid kappa receptor agonist for drug dependence.Ann N Y Acad Sci. 2004 Oct;1025:404-13. doi: 10.1196/annals.1316.050. Ann N Y Acad Sci. 2004. PMID: 15542743 Review.
-
Opioids in preclinical and clinical trials.Top Curr Chem. 2011;299:29-62. doi: 10.1007/128_2010_74. Top Curr Chem. 2011. PMID: 21630515 Review.
Cited by
-
Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor.Cell Signal. 2017 Apr;32:59-65. doi: 10.1016/j.cellsig.2017.01.016. Epub 2017 Jan 11. Cell Signal. 2017. PMID: 28088389 Free PMC article.
-
Modeling genetic imprinting effects of DNA sequences with multilocus polymorphism data.Algorithms Mol Biol. 2009 Aug 11;4:11. doi: 10.1186/1748-7188-4-11. Algorithms Mol Biol. 2009. PMID: 19671182 Free PMC article.
-
Preclinical Studies on Nalfurafine (TRK-820), a Clinically Used KOR Agonist.Handb Exp Pharmacol. 2022;271:137-162. doi: 10.1007/164_2021_443. Handb Exp Pharmacol. 2022. PMID: 33834276 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials